The Competition Tribunal has conditionally approved (21 January) CP Spruce Holdings’ acquisition of Baxter International Inc.’s kidney care segment, Vantive. The approval includes measures to address concerns over product supply continuity and pricing stability.
Vantive specializes in renal replacement therapy (RRT) products used for patients with end-stage renal disease. While Vantive has no production facilities in South Africa, its products are supplied to a local hospital and critical care manufacturer.
CP Spruce, a Luxembourg-based partnership, is part of a global asset management group with existing South African interests, though none overlap with Vantive’s market. The merger has also been notified to competition authorities globally.
